NHS England has published a statement regarding commissioning decisions for HPV primary screening in the cervical screening programme.
The Fetal Anomaly Screening Programme (FASP) team has revamped and updated the 18+0 to 20+6 week fetal anomaly scan e-learning resource. It now covers all bases in just 6 stand-alone units and is shorter and much easier to navigate than its predecessor. This module …
We (the NHS Sickle Cell and Thalassaemia Screening Programme) are pleased to announce the launch of our new e-learning resource on the CPD website to support greater understanding of the programme, the conditions screened for and how they can impact on individuals …
We have updated our very popular resource cards for midwives to reflect the fact that screening for rubella susceptibility in pregnancy ended on 1 April 2016.
The NHS Newborn Hearing Screening Programme (NHSP) has played a major role in identifying moderate and profound hearing loss in newborn babies. Before the introduction of the NHSP, half of the children with moderate and profound hearing loss were not …
We are delighted to have published the first ever NHS Newborn and Infant Physical Examination (NIPE) Screening Programme Handbook, which informs practitioners who carry out the NIPE examination and supports best clinical screening practice.
March was a busy month for the NHS Newborn Blood Spot (NBS) Screening Programme and we’re now delighted to announce the publication of some great new resources.
We are changing the way we store and distribute leaflets and other printed materials for our cancer screening programmes. This will affect all our clients who order our breast, cervical and bowel cancer screening resources.
Antenatal screening for rubella (German measles) susceptibility stops on 1 April 2016.
Every year, we, the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme, publish a data report, which evaluates the performance of the programme.
PHE Screening has published an updated information pack to help GPs and primary care professionals advise well men aged 50 and over about prostate specific antigen (PSA) testing for prostate cancer.